Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma

International Journal of Hematology

Volumn 97, Issue 6, 2013, Pages 743-748

  Harada, Takeshi ^a   Ozaki, Shuji ^a,c   Oda, Asuka ^a   Fujii, Shiro ^a   Nakamura, Shingen ^a   Miki, Hirokazu ^a,b   Kagawa, Kumiko ^a   Takeuchi, Kyoko ^a   Matsumoto, Toshio ^a   Abe, Masahiro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^c TOKUSHIMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Inflammatory reaction; Lenalidomide; Multiple myeloma

Indexed keywords

BORTEZOMIB; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; LENALIDOMIDE; MELPHALAN; PREDNISOLONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; LOW DRUG DOSE; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOKINES; DEXAMETHASONE; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; TH1 CELLS; TH2 CELLS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84879151676     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1321-0     Document Type: Article

References (20)

1. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133-42.
2. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29-37.
3. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106(13):4050-3.
4. Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23(11):2147-52.
5. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123-32.
6. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22-32.
7. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2(36):36.
8. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163(1):380-6.
9. Ozaki S, Harada T, Fujii S, Nakamura S, Miki H, Nakano A, et al. Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma. Int J Hematol. 2011;93(2):257-9.
10. Morita Y, Shimada T, Yamaguchi T, Rai S, Hirase C, Emoto M, et al. Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide. Int J Hematol. 2011;94(6):583-4.
11. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-54.
12. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-20.
13. Picker LJ, Singh MK, Zdraveski Z, Treer JR, Waldrop SL, Bergstresser PR, et al. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood. 1995;86(4):1408-19.
14. Openshaw P, Murphy EE, Hosken NA, Maino V, Davis K, Murphy K, et al. Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. J Exp Med. 1995;182(5):1357-67.
15. Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood. 1995;85(3):765-71.
16. Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets. 2010;10(2):155-67.
17. Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. 2011;117(5):1605-13.
18. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111(11):5291-7.
19. Chanan-Khan AA, Chitta K, Ersing N, Paulus A, Masood A, Sher T, et al. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol. 2011;155(4):457-67.
20. Aue G, Njuguna N, Tian X, Soto S, Hughes T, Vire B, et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica. 2009;94(9):1266-73.